LLS and blood cancer advocates are celebrating after our efforts helped make two bills become law in California, advancing health equity and improving cancer care for thousands.
Today, cancer patients—and others with other chronic conditions—are breathing a collective sigh of relief. After years of relentless efforts by LLS staff and blood cancer advocates, President Biden just signed into law the Inflation Reduction Act and its key health provisions which will make healthcare more affordable for millions.
The Food and Drug Administration (FDA) approved azacitidine (Vidaza®) for pediatric patients 1 month and older with newly diagnosed juvenile myelomonocytic leukemia (JMML). JMML is an aggressive and difficult to treat disease.
New York’s newly-signed budget contains a key reform that could be nothing short of lifesaving for some cancer patients living in the state. National Cancer Institute-designated cancer centers will become “in-network” for over 5 million New Yorkers who rely on Medicaid, Essential, or Marketplace plans.
The U.S. Food and Drug Administration (FDA) last week approved axicabtagene ciloleucel (axi-cel, Yescarta®) for patients with large B-cell lymphoma (LBCL) who either did not respond to first-line standard chemotherapy or relapsed within 12 months. This is a big step for CAR T because it is now proven that CAR T-therapy can outperform the best therapy we had for certain patients that failed initial therapy.